Compare FTAI & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | FTAI | VTRS |
|---|---|---|
| Founded | 2011 | 1961 |
| Country | United States | United States |
| Employees | 985 | 30000 |
| Industry | Misc Corporate Leasing Services | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 23.4B | 18.7B |
| IPO Year | N/A | 2019 |
| Metric | FTAI | VTRS |
|---|---|---|
| Price | $205.88 | $17.49 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 4 |
| Target Price | ★ $274.67 | $13.50 |
| AVG Volume (30 Days) | 1.1M | ★ 9.1M |
| Earning Date | 04-29-2026 | 05-07-2026 |
| Dividend Yield | 0.75% | ★ 3.21% |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.15 |
| Revenue | N/A | ★ $14,299,900,000.00 |
| Revenue This Year | $32.73 | $4.41 |
| Revenue Next Year | $51.41 | $1.96 |
| P/E Ratio | ★ $65.85 | $115.50 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $109.90 | $8.63 |
| 52 Week High | $323.51 | $17.53 |
| Indicator | FTAI | VTRS |
|---|---|---|
| Relative Strength Index (RSI) | 35.34 | 66.52 |
| Support Level | $157.96 | $15.82 |
| Resistance Level | $269.05 | N/A |
| Average True Range (ATR) | 14.39 | 0.45 |
| MACD | -4.87 | 0.10 |
| Stochastic Oscillator | 8.51 | 91.20 |
FTAI Aviation Ltd is an independent engine maintenance platform focused on the CFM56-5B, CFM56-7B, and V2500 aircraft engines, which power the 737NG and A320ceo aircraft. The company repairs and rebuilds engines in its maintenance facilities and with joint venture partners, and sells or leases engines through its proprietary Maintenance, Repair and Exchange (MRE) model under the Aerospace Products segment, which earns maximum revenue from North America and develops, repairs/refurbishes, and sells aircraft engines and aftermarket components. It also operates an Aviation Leasing segment, owning and managing a portfolio of on- and off-lease aircraft and engines, including engine transfers for rebuilding and sales.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.